Is Former CStone Chairman the Medicine Ailing Hengrui Needs?
Hengrui Medicine started the New Year by naming CStone’s previous top official Jiang Ningjun as its new vice general manager and chief strategy officer.Key Takeaways:Hengrui Pharma has named the former…
Product Approval Breathes New Life Into Boan Biotech IPO
The biosimilar drug maker was approved to sell its second new product in China last month as it applies to list in Hong KongKey Takeaways:Boan Biotechnology has filed for a…
Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas
Cancer drug maker ended a tie-up to bring one of its drugs to North America last week, less than two months after its best-selling product was rejected by the FDA…
Junshi Biosciences Back in the Red, Pins Hopes on Covid Drugs
The innovative drug developer reported a first-quarter loss as a result of a steep drop in licensing revenue Key Takeaways: Junshi Biosciences’ revenue tumbled 61% in the first quarter, reflecting…
RELATED ARTICLES
-
Hengrui Pharma accelerates bid for global brand status
600276.SHG -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Former TV magnate tries his luck at EVs with IPO plans in sight
-
No respite for RemeGen as problems and losses pile up
9995.HK 688331.SHG
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
